Theriva Biologics (SFY0) Stock Statistics & Valuation Metrics

Theriva Biologics has a market cap or net worth of €8.49M. The enterprise value is €3.70M.

Theriva Biologics has 45,892,690 shares outstanding. The number of shares has decreased by -2.65% in one year.

Theriva Biologics’s return on equity (ROE) is -1.64 and return on invested capital (ROIC) is -52.10%.

The current PE Ratio of Theriva Biologics is ―. Theriva Biologics’s PEG ratio is 0.00114.

In the last 12 months, Theriva Biologics had revenue of 0.00 and earned -25.25M in profits. Earnings per share was -2.08.

In the last 12 months, operating cash flow was -12.35M and capital expenditures -22.00K, giving a free cash flow of -12.38M billion.

Theriva Biologics pays an annual dividend of ―, resulting in a dividend yield of ―

Theriva Biologics upcoming earnings date is Nov 17, 2026, After Close (Confirmed).

Theriva Biologics as a current ratio of 1.74, with Debt / Equity ratio of 29.15%

In the past 12 months, Theriva Biologics has paid 1.51M in taxes.

Theriva Biologics EV to EBITDA ratio is 0.33, with an EV/FCF ratio of 0.47.

Theriva Biologics has €11.34M in cash and marketable securities with €3.55M in debt, giving a net cash position of €7.78M billion.

Gross margin is 92.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Theriva Biologics is €0.89, which is 11.43% higher than the current price. The consensus rating is Moderate Buy